文献速递胸部肿瘤

液体活检能否替代组织EGFR检测?

Are liquid biopsies a surrogate for tissue EGFR testing?
PubMed 文献 · Ann Oncol · 2018-01-01

该综述总结了液体活检检测EGFR敏感突变及耐药突变(如T790M)的技术及其在治疗决策中的适用性,指出组织基因分型虽是金标准但受组织可及性和活检并发症限制,而液体活检作为血液样本检测肿瘤基因组的方法具有可行性。

要点

  • 液体活检可检测EGFR敏感突变和获得性耐药突变如T790M。
  • 组织基因分型是当前临床金标准但受组织可及性和活检并发症限制。
  • 液体活检结果可用于指导治疗决策。

核心结论

  • 液体活检为检测EGFR敏感和耐药突变提供了可行手段,可辅助治疗决策。

研究设计与样本

  • 综述,总结液体活检技术及其在检测EGFR敏感和耐药突变中的适用性。

主要发现

  • 液体活检可通过血液样本评估肿瘤基因组。

临床怎么用

  • 液体活检结果可用于指导EGFR突变阳性非小细胞肺癌的治疗决策。

局限性

  • 组织基因分型受组织可及性和活检并发症限制,液体活检的局限性未在摘要中详述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular profiling has changed the treatment landscape in advanced non-small-cell lung cancer. Accurately identifying the tumours that harbour sensitizing EGFR mutations, the most common targetable molecular alteration, as well as those with acquired resistance mutations (e.g. T790M) on treatment is a high clinical priority. The current clinical gold standard is genotyping of tumour specimens. However, the practical utility of this approach is limited by the lack of available tissue and the potential complications associated with biopsies. With the advent of newer sequencing assays, it has become feasible to assess tumour genomics via a blood sample, termed a 'liquid biopsy'. In this review, we summarize the available techniques for liquid biopsies and their applicability for detecting sensitizing and resistance EGFR mutations and how these results may be used for making treatment decisions.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Goldman JW, Noor ZS, Remon J, et al. Are liquid biopsies a surrogate for tissue EGFR testing? Ann Oncol. 2018. PMID: 29462257. doi:10.1093/annonc/mdx706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。